SKAN increases stake in Aseptic Technologies to 90 percent
|
SKAN AG
/ Key word(s): Miscellaneous
Media information SKAN increases stake in Aseptic Technologies to 90 percent Allschwil, May 31, 2024 - SKAN Group AG, world market leader for high-quality isolator systems for aseptic production processes in the (bio-)pharmaceutical industry, has increased its stake in the Belgian subsidiary Aseptic Technologies as planned. As of May 30, 2024, it has acquired a further 5% of the shares from the co-owner, Wallonie Entreprendre (WE), increasing its shareholding to 90%. The parties have agreed not to disclose the purchase price. The shareholding in Aseptic Technologies will remain unchanged for the time being and the co-owner will continue to support Aseptic Technologies and SKAN with his 10% shareholding. Aseptic Technologies is of strategic importance for the SKAN Group. The automated, robot-assisted process solutions for filling closed vials (AT-Closed Vial® Technology) target applications in cell and gene therapy and thus a strongly growing therapeutic segment. There are currently seven drugs sold in the AT-Closed Vial® that have been approved in a total of 15 countries/regions. Aseptic Technologies' customers have an estimated 450 compounds in research and clinical trials, several of which are in the final stages of development before market approval. The commercialization of new drugs will increase the demand for AT-Closed Vials® and thus the volume in the Services & Consumables segment. As a result of the increase of the stake in Aseptic Technologies, SKAN Group AG's indirectly held interest in Plast4Life also increases to 22.05%. Plast4Life is a company in Belgium that is still being built up and will be manufacturing AT-Closed Vials® in the future using the plastic injection moulding process.
Thomas Balmer, ir@skan.com, +41 79 703 87 28
SKAN – together always one step ahead SKAN is a pioneer in the field of aseptic and aseptic-toxic manufacturing processes for the (bio)pharmaceutical industry. The company is the market and technology leader for high-quality, process-critical isolator systems for filling drugs according to strict sterility standards. In addition, the company offers its customers process support, services and consumables. Innovative solutions and an efficient life-cycle support organisation make SKAN an important partner for the pharmaceutical and biotech industry, CMOs (Contract Manufacturing Organisations) and research laboratories worldwide. Founded in 1968, SKAN today employs approximately 1400 people. More than half of them work at the Allschwil headquarters in the Life Sciences Hub of the Basel region. The other employees are located among the subsidiaries in Switzerland, Germany, Belgium, Japan, the USA and Brazil.
End of Media Release |
| Language: | English |
| Company: | SKAN AG |
| Kreuzstrasse 5 | |
| 4123 Allschwil | |
| Switzerland | |
| Phone: | +41 43 268 32 32 |
| E-mail: | info@skan.com |
| ISIN: | CH0013396012 |
| Valor: | 1339601 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1914867 |
| End of News | EQS News Service |
|
|
1914867 31.05.2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.